# Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems

> **NCT00626236** · PHASE2 · COMPLETED · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 78 (actual)

## Conditions studied

- Attention Deficit Disorder With Hyperactivity
- Conduct Disorder

## Interventions

- **DRUG:** SPN-810
- **DRUG:** SPN-810
- **DRUG:** SPN-810
- **DRUG:** SPN-810

## Key facts

- **NCT ID:** NCT00626236
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-21
- **Primary completion:** 2009-09-23
- **Final completion:** 2009-09-23
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2025-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00626236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00626236, "Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00626236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*